Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06174987 · ClinicalTrials.gov registry record · Phase 3
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
A Phase 3 study of Advanced Cancer and Metastatic Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT06174987 is a Phase 3 study of Advanced Cancer and Metastatic Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 50 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT06174987, a Phase 3 study of Advanced Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Conditions Studied
Interventions
- DRUG T-DXd
Study Locations (20)
Other
- Flinders Medical Center - Bedford Park
- Monash Medical Center - Melbourne
- Grand Hôpital de Charleroi - Charleroi
- Instituto Aericas - Rio de Janeiro
- A.C. Camargo Cancer Center - São Paulo
- IBCC Nucleo de Pequisa e Ensino - São Paulo
- Institut Gustave Roussy - Villejuif
- Rabin Medical Center - Petah Tikva
- Ospedale San Raffaele - Milan
- Istituto Nazionale Tumori Fondazione G. Pascale - Naples
- National Cancer Center Hospital - Chūō
- Kyungpook National University Chilgok Hospital - Daegu
- National Cancer Center - Gyeonggi-do
- Seoul National University Bundang Hospital - Gyeonggi-do
- Seoul National University Hospital - Jongno-gu
- Severance Hospital, Yonsei University - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
Florida
- Miami Cancer Institute - Miami
North Carolina
- Duke University - Trent Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2028-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06174987
The ClinicalTrials.gov registry entry for NCT06174987 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which T-DXd is the first listed.
NCT06174987 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06174987 about?
NCT06174987 is a clinical study titled "A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)". This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207,...
What is the current status of trial NCT06174987?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2024-01-05. Estimated completion is 2028-01-17.
What conditions does trial NCT06174987 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT06174987?
The interventions under investigation include: T-DXd (DRUG).
Who is sponsoring clinical trial NCT06174987?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06174987 being conducted?
This trial has 20 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
COMPLETED · Phase 3
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.